Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
HMG-CoA Reductase Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, HMGCR) is a rate-controlling enzyme of the mevalonate pathway, which produces cholesterol. HMGCR catalyzes the conversion of HMG-CoA to mevalonic acid, a necessary step in the biosynthesis of cholesterol. HMG-CoA reductase inhibitors, competitively reduce inhibit the enzyme HMG-CoA reductase, and thereby reducing hepatic cholesterol concentrations, which stimulates the upregulation of hepatic low-density lipoprotein (LDL) receptors which increases hepatic uptake of LDL. HMG-CoA reductase inhibitors are indicated as an adjunct to diet in the treatment of triglyceridemia, primary dysbetalipoproteinemia, and homozygous familial hypercholesterolemia. It is also indicated for the prevention of major cardiovascular events such as myocardial infarction, nonfatal stroke, and coronary artery revascularization. JW Pharma, Boryung Group, Kowa Pharmaceutical America, Eli Lilly & Company, Merck (MSD), Alvogen, and Daiichi Sankyo Pharmaceutical are the major players in the HMG-CoA reductase inhibitors market.
Key Market Developments:
Approved Drug Molecules and Brand Names for HMG-CoA Reductase Inhibitors:
Drugs under the Pipeline for HMG-CoA Reductase Inhibitors:
Clinical Activity and Developments of HMG-CoA Reductase Inhibitors:
Currently, there are about 60 drug products in the HMG-CoA reductase inhibitors, including more than 20 approved drugs in the market, and others in the clinical development phases
Molecule Name |
Number of Studies |
Livasartan (Pitavastatin/Valsartan) |
7 |
modified-release formulation of Lovastatin lactone (SYN-010) |
5 |
Metformin/Rosuvastatin (HCP1201) |
4 |
Amlodipine/Rosuvastatin (DP-R212) |
3 |
Amlodipine/valsartan (IN-C008) |
2 |
Amlodipine/rosuvastatin/telmisartan (DW-1501) |
2 |
Atorvastatin immediate-release/Losartan potassium delayed release (HL 040) |
2 |
Ezetimibe/Rosuvastatin (DP-R207) |
2 |
Ezetimibe/Rosuvastatin (NVP-1205) |
2 |
Rosuvastatin/omega-3 fatty acid (HCP 1007) |
2 |
Rosuvastatin/omega-3-acids ethyl esters (HCP1105) |
2 |
AmosartanQ (Amlodipine/Losartan/Rosuvastatin) |
1 |
ClowZ Tab (Ezetimibe/Rosuvastatin) |
1 |
Copaxone/Zocor (Glatiramer acetate/Simvastatin) |
1 |
Lipimet SR (Atorvastatin/Metformin) |
1 |
Metformin/Rosuvastatin (BCWP_C003 |
1 |
Olpadronic acid (IG-8801) |
1 |
Rosuvastatin/Valsartan |
1 |
HMG-CoA reductase inhibitors such as rosuvastatin, simvastatin, atorvastatin, pravastatin, and others are primarily indicated for the conditions like diabetes mellitus, clinical atherosclerosis including myocardial infarction, acute coronary syndromes, stable angina, stroke, ischemic attack, peripheral artery disease, claudication, and abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels. A number of drug molecules are in ongoing clinical trial phases for conditions like dyslipidemia, hypertension, hypercholesterolemia, and hyperlipidemia.
Download Free Sample Report
Atorvastatin, Simvastatin, Rosuvastatin, Pravastatin, Ezetimibe/Simvastatin, Livalo (Pitavastatin), Lovastatin, and Fluvastatin are some of the approved HMG-CoA reductase inhibitors in the market.
JW Pharma, Boryung Group, Kowa Pharmaceutical America, Eli Lilly & Company, Merck (MSD), Alvogen, and Daiichi Sankyo Pharmaceutical are the major market players in the HMG-CoA reductase inhibitors.
Major indications for HMG-CoA reductase inhibitors are triglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, diabetes mellitus, abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.
There are about 16 drug molecules in the phase-I/II clinical development for HMG-CoA reductase inhibitors.
Key Market Players